Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset

Authors

  • M. Nomoto,

    1. MRC Movement Disorders Research Group, University Department of Neurology and Parkinson's Disease Research Centre, Institute of Psychiatry and King's College Hospital Medical School, Denmark Hill, London
    Search for more papers by this author
  • S. Stahl,

    1. Merck, Sharp and Dohme, Neuroscience Research Centre, Terlings Park, Harlow, Essex, United Kingdom
    Search for more papers by this author
  • P. Jenner,

    1. MRC Movement Disorders Research Group, University Department of Neurology and Parkinson's Disease Research Centre, Institute of Psychiatry and King's College Hospital Medical School, Denmark Hill, London
    Search for more papers by this author
  • Dr. C. D. Marsden

    Corresponding author
    1. MRC Movement Disorders Research Group, University Department of Neurology and Parkinson's Disease Research Centre, Institute of Psychiatry and King's College Hospital Medical School, Denmark Hill, London
    • Institute of Psychiatry, University of London, de Crespigny Park, Denmark Hill, London SE5 8AF, England
    Search for more papers by this author

Abstract

Administration of MPTP (1–4 mg/kg ip daily for 5–7 days) to common marmosets induced persistent parkinsonian motor deficts. The subcutaneous adminstration of (+)-PHNO [(+)-4-propyl-9-hydroxynaphtoxazine; 1–4 μ/kg] caused a dose-dependent reversal of the akinesia and incoordination of movement. Similarly, oral administration of (+)-PHNO (5–20 μ/kg) caused an equivalent reversal of the motor abnormalities. No dyskinetic phenomena were induced by (+)-PHNO on oral or subcutaneous administration. Oral or subcutaneous administration of (+)-PHNO to normal control marmosets also increased the usual repetoire of motor behaviour, but this was not as marked as in MPTP-treated animals. (+)-PHNO is a potent dopamine agonist drug of potential use in the treatment of Parkinson's disease.

Ancillary